한글목차

세계 아달리무맙 바이오시밀러 시장의 미래는 병원 약국 시장과 소매 약국 시장에 기회가 있어 유망합니다. 세계 아달리무맙 바이오시밀러 시장은 2025-2031년간 21.6%의 연평균 복합 성장률(CAGR)로 성장하여 2031년까지 약 34억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 관절염의 유병률 증가와 피부 질환 증가입니다.

• Lucintel의 예측에 따르면, 제품 카테고리에서 엑센피아는 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.
• 아달리무맙 바이오시밀러는 다양한 자가면역질환 치료에 사용되며, 일반적으로 병원 전문의가 관리하기 때문에 병원 약국이 최종 사용 카테고리에서 가장 큰 부문을 차지할 것입니다.
• 지역별로는 류마티스 관절염 유병률 증가와 노인 인구 증가로 인해 북미가 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다.

아달리무맙 바이오시밀러 시장의 전략적 성장 기회/p>

아달리무맙 바이오시밀러 시장의 주요 부문은 다양한 용도의 전략적 성장 기회입니다. 성장 시장은 이해관계자들이 시장 수요에 대응하고 새로운 트렌드를 활용하여 큰 성장 기회를 실현할 수 있는 시장입니다. 주요 응용 분야는 성장과 혁신의 잠재력이 두드러지게 나타나는 분야입니다.

• 시장 확대 신흥 시장 : 신흥국 시장, 특히 아시아와 라틴아메리카에서 아달리무맙 바이오시밀러 제제가 크게 성장할 것으로 예상됩니다. 이들 지역에서는 보다 합리적인 가격의 바이오의약품에 대한 수요가 증가하고 있기 때문입니다. 다른 전략으로는 현지 파트너십을 통한 제조 및 시장 접근성을 개선하고 현지 의료 수요를 충족시킬 수 있도록 설계된 가격 책정 모델을 채택하는 것 등이 있습니다.
• 새로운 바이오시밀러 의약품 개발: 아달리무맙의 제형과 전달 방법을 개선한 새로운 바이오시밀러 개발은 더 많은 잠재력을 가지고 있습니다. 제품 혁신에는 서방형 제형, 병용 요법 또는 환자의 요구를 더 잘 충족시키는 다른 제형이 포함될 수 있습니다. 바이오시밀러 의약품 연구개발에 대한 투자는 시장 점유율을 확대하고 성장을 가속할 수 있습니다.
• 전략적 파트너십 및 제휴: 바이오시밀러 제약사, 의료 서비스 제공업체 및 지불자 간의 전략적 파트너십은 아달리무맙 바이오시밀러 시장 내 입지를 강화할 수 있습니다. 제휴 계약은 합작 투자, 공동 마케팅 계약, 판매 제휴 등 다양한 형태로 이루어질 수 있습니다. 이러한 제휴는 시장 접근성을 제공하고, 제품 인지도를 높이며, 바이오시밀러의 채택 곡선을 원활하게 할 수 있습니다.
• 의료 시스템 통합: 바이오시밀러가 기존 의료 시스템에 통합될 수 있도록 처방전 및 가이드라인에 바이오시밀러를 포함시키는 것이 채택을 촉진하는 데 도움이 됩니다. 또한, 바이오시밀러가 치료 프로토콜과 보험 상환 일정에 포함될 수 있도록 의료 당국과 협력하는 것이 필수적입니다. 이러한 통합은 의료 시스템에서 보다 폭넓은 사용과 비용 절감에 기여할 수 있습니다.
• 환자 교육: 환자 교육 및 인식 개선 프로그램에 대한 투자는 성장의 기회가 될 수 있습니다. 환자들에게 바이오시밀러의 장점과 안전성에 대해 교육하면 거부감을 극복하고 수용성을 높일 수 있습니다. 효과적인 커뮤니케이션 전략과 교육 캠페인은 환자의 신뢰를 높이고 바이오시밀러로의 원활한 전환을 촉진할 수 있습니다.

아달리무맙 바이오시밀러 시장의 전략적 성장 기회는 신흥 시장 진출, 비용 우위 활용, 전략적 파트너십 형성 등을 들 수 있습니다. 이러한 기회는 시장 확대를 촉진하고, 환자 접근성을 향상시키며, 바이오시밀러 개발의 혁신을 촉진할 것입니다.

아달리무맙 바이오시밀러 시장 성장 촉진요인 및 과제

아달리무맙 바이오시밀러 시장 역학은 기술적, 경제적, 규제적 요인의 영향을 받고 있으며, 이는 시장 성장에 기여하는 동시에 큰 도전이 되고 있습니다. 이해관계자들은 역동적으로 변화하는 상황에 효과적으로 대응하기 위해 이러한 촉진요인과 과제를 인식하고 있어야 합니다. 기술 발전, 경제적 압력, 규제 변화 등 이 모든 요인들이 함께 시장 역학을 형성하고 개발 및 승인에서 시장 출시 및 경쟁에 이르기까지 모든 것에 영향을 미치고 있습니다.

아달리무맙 바이오시밀러 시장을 주도하는 요인은 다음과 같습니다.

• 휴미라 특허 만료: 휴미라 특허 만료: 휴미라 특허가 2023년 만료되는 것은 바이오시밀러 시장을 견인하는 요인으로 보입니다. 많은 바이오시밀러가 시장에 진입할 수 있는 길이 열리고, 가격을 낮추고, 생물학적 제제 치료 접근성을 확대하는 경쟁 환경이 조성될 것입니다. 특허 클리프는 바이오시밀러 개발에 대한 투자를 촉진하여 환자의 치료 옵션을 확대할 수 있습니다.
• 비용 효율성: 바이오시밀러가 채택되는 주요 원동력은 오리지널 생물학적 제제에 대한 저렴한 치료 대안을 제공하는 것입니다. 의료 시스템과 지불자는 약제비 절감에 점점 더 중점을 두고 있으며, 바이오시밀러는 오리지널 생물학적 제제 대비 상당한 비용 절감 효과를 기대할 수 있습니다. 이러한 비용 이점은 바이오시밀러가 널리 채택되고 치료 요법에 통합될 수 있는 원동력이 될 수 있습니다.
• 규제 당국의 지원: FDA는 EMA 등 다른 기관과 함께 아달리무맙 바이오시밀러의 승인 및 시장 진입을 위한 규제 프레임워크를 구축했습니다. 임상시험 간소화, 가이드라인 투명화 등 간소화된 승인 절차는 시장 진입 장벽을 낮추고 시장 출시를 가속화할 수 있습니다.
• 환자 수요 증가: 저렴하고 효과적인 치료제를 찾는 환자들 수요가 증가하면서 바이오시밀러의 채택이 증가하고 있습니다. 바이오시밀러에 대한 인식이 높아짐에 따라 환자들은 비용절감형 치료제를 찾고 있습니다. 이러한 추세는 환자 중심적이고 비용 효율적인 헬스케어 솔루션에 대한 전반적인 수요를 촉진하고 있습니다.
• 의료 시스템으로부터의 압력: 약품 비용과 치료 접근성 측면에서 세계 의료 시스템에 대한 압력이 증가하고 있습니다. 바이오시밀러 의약품은 저렴한 비용으로 유사한 치료 효과를 제공함으로써 해결책을 제시할 수 있습니다. 의료 예산에 대한 경제적 부담은 바이오시밀러 도입의 원동력이 되고 있으며, 치료 수준을 유지하면서 비용 절감을 달성하는 데 도움이 되고 있습니다.

아달리무맙 바이오시밀러 시장의 과제는 다음과 같습니다.

• 규제적 장애물: 규제적 장애물: 규제적 장애물: 지원적 프레임워크는 있지만, 바이오시밀러의 승인 절차는 여전히 복잡하고 지역별로 차이가 있습니다. 다양한 규제 요건을 충족하고 오리지널 의약품과의 동등성을 입증하기 위해서는 임상시험과 문서화에 많은 투자가 필요합니다. 이러한 규제 장벽은 시장 진입을 지연시키고 개발 비용을 증가시킬 수 있습니다.
• 시장 수용성: 바이오시밀러 의약품의 효능과 안전성에 대한 우려로 인해 오리지널 생물학적 제제에 비해 시장 수용이 늦어지고 있습니다. 생소함과 위험에 대한 인식으로 인해 의사와 환자들은 전환에 대한 거부감을 가질 수 있으며, 이는 채택률에 영향을 미칠 수 있습니다. 이러한 장애물은 확실한 증거와 효과적인 교육 활동을 통해 극복할 수 있습니다.
• 지적재산권 분쟁: 특허 분쟁 및 소송을 포함한 지적재산권 문제는 바이오시밀러 개발 기업이 직면한 중요한 과제입니다. 독점권이나 특허권을 둘러싼 법정 투쟁은 시장 진입을 지연시키고 비용을 증가시킬 수 있습니다. 이러한 분쟁은 시장의 경쟁 역학에 영향을 미칠 수 있기 때문에 적절한 법적 접근을 통해 신중하게 협상해야 합니다.

아달리무맙 바이오시밀러 시장 성장 촉진요인으로는 특허 만료, 비용 효율성, 규제 당국의 지원, 환자 수요, 의료 시스템의 압력 등을 꼽을 수 있습니다. 반면, 규제적 장애물, 시장 수용성, 지적재산권 관련 분쟁과 같은 과제도 해결해야 합니다. 이러한 추진 요인과 과제가 결합하여 시장 역학에 영향을 미치고, 채택률, 경쟁 및 전체 시장 성장에 영향을 미칩니다. 이러한 추진력을 활용하는 것이 이러한 과제를 극복하는 열쇠가 될 것으로 보입니다.

목차

제1장 주요 요약

제2장 세계의 아달리무맙 바이오시밀러 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 아달리무맙 바이오시밀러 시장 동향(2019-2024년)과 예측(2025-2031년)
• 아달리무맙 바이오시밀러 세계 시장, 제품별
  • Exemptia
  • Adalirel
  • Cipleumab
  • 기타
• 아달리무맙 바이오시밀러 세계 시장, 최종 용도별
  • 병원 약국
  • 소매 약국
  • 기타

제4장 시장 동향과 예측 분석(2019-2031년), 지역별

• 아달리무맙 바이오시밀러 시장, 지역별
• 북미의 아달리무맙 바이오시밀러 시장
• 유럽의 아달리무맙 바이오시밀러 시장
• 아시아태평양의 아달리무맙 바이오시밀러 시장
• 기타 지역의 아달리무맙 바이오시밀러 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 아달리무맙 바이오시밀러 시장 성장 기회, 제품별
  • 세계의 아달리무맙 바이오시밀러 시장 성장 기회, 최종 용도별
  • 세계의 아달리무맙 바이오시밀러 시장 성장 기회, 지역별
• 세계 아달리무맙 바이오시밀러 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 아달리무맙 바이오시밀러 시장 생산능력 확대
  • 세계의 아달리무맙 바이오시밀러 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증과 라이선싱

제7장 주요 기업 개요

• Alfred E. Tiefenbacher
• Amgen
• Boehringer Ingelheim
• Glenmark
• Zydus
• Torrent Pharmaceuticals
• Reliance Life Sciences

영문목차

The future of the global adalimumab biosimilar market looks promising with opportunities in the hospital's pharmacy and retail pharmacy markets. The global adalimumab biosimilar market is expected to reach an estimated $3.4 billion by 2031 with a CAGR of 21.6% from 2025 to 2031. The major drivers for this market are the growing incidence of arthritis and the rising number of skin disorders.

• Lucintel forecasts that, within the product category, exemptia is expected to witness the highest growth over the forecast period.
• Within the end-use category, hospital pharmacies will remain the largest segment because adalimumab biosimilars are used to treat a variety of autoimmune diseases, which are typically managed by specialists in hospital settings.
• In terms of regions, North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis and the rise in the geriatric population.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Adalimumab Biosimilar Market

The adalimumab biosimilar market has become quite dynamic, driven by multiple emerging trends. These trends have reshaped the way biosimilars are developed, marketed, and adopted, and are transforming competition and market strategy globally. Understanding these trends is essential for stakeholders aiming to navigate the evolving landscape.

• Increased Competition in the Market: With many biosimilars entering the market, competition has increased, prices have dropped, and patient access has improved. This trend is evident worldwide, with several companies competing by offering differentiated products and strategic pricing. This growing competition is fostering innovation in biological treatments, improving access for both providers and patients.
• Regulatory Flexibility: Regulatory bodies are increasingly adopting flexible approaches to facilitate the approval of biosimilars. For example, both the FDA and EMA have streamlined their approval pathways, enabling quicker market access. This will significantly enhance access to more affordable treatment options and create a more competitive market environment. Additional regulatory frameworks are expected to sustain the growth in biosimilar adoption.
• Focus on Patient Access and Affordability: There is a growing focus on enhancing patient access through affordability initiatives involving biosimilars. Payers and healthcare systems are implementing policies, such as pricing negotiations and formulary inclusions, to promote the use of biosimilars. These measures aim to reduce treatment costs while improving access to essential therapies-an imperative for global healthcare.
• Greater Stringency in Clinical Data: As biosimilars gain prevalence, there is a shift toward requiring more robust clinical data to substantiate safety and efficacy. This trend arises from increased scrutiny by regulatory bodies and healthcare providers. In response, companies are investing in extensive clinical trials to meet these requirements, influencing development timelines and overall costs.
• Value-Based Pricing Model Adoption: The adoption of value-based pricing is becoming more common in the biosimilar market. In this model, the price of a product is based on the therapeutic value it provides. This approach aligns with efforts to improve cost-effectiveness and patient outcomes. Value-based pricing is expected to drive market dynamics by incentivizing the use of biosimilars and easing some of the economic burdens faced by healthcare systems.

Emerging trends in the adalimumab biosimilar market indicate a wave of increasing competition, innovation, and access. Developmental advancements in biosimilars will lead to higher-quality products with more streamlined regulatory pathways. A key trend in the market is cost reduction, with competitive pricing driving the entry of multiple biosimilars into the market.

Recent Developments in the Adalimumab Biosimilar Market

Recent developments in the adalimumab biosimilar market have completely changed the face of biological therapies. These developments reflect not only advancements in biosimilar technology but also changes in regulations and market dynamics. Understanding these key developments provides insight into the ways in which the market is evolving and what stakeholders can expect in the future.

• Humira Patent Expirations: When Humira's patents expired in 2023, it marked a pivotal moment in the market for biosimilars. Many biosimilars began to enter the market, and with increasing competition, prices were driven down. Biosimilars such as Amesite and Hulin have been released, offering wider treatment options and greater accessibility to biological therapies.
• Regulatory Approvals and Market Entry: Recently, various biosimilars of Adalimumab have gained regulatory approval for market entry. For example, the FDA-approved drugs such as Amesite and Mylan's Hulin, accelerate their availability. These approvals are crucial for increasing competition in the market and providing a wider range of options for both patients and healthcare providers.
• Pricing Strategies and Market Penetration: Biosimilars have entered the market with competitive pricing strategies to capture market share. Companies are adopting various pricing models, such as discounts and value-based pricing, to attract healthcare providers and payers. This trend is reshaping market dynamics and increasing the adoption of biosimilars.
• Rise in Clinical Trials: Clinical trials testing Adalimumab biosimilars for their safety and efficacy have increased. These trials are essential for regulatory approvals and help to address concerns about the performance of biosimilars compared to the reference product. More robust clinical data facilitates market entry and instills greater confidence among key stakeholders.
• Market Penetration into Emerging Economies: Biosimilars of Adalimumab are gaining rapid acceptance in emerging economies such as India and China. Local players are introducing more biosimilar products at affordable prices, and government policies encourage their use. This expansion highlights the growing global market and the increasing demand for cost-effective treatment solutions in these regions.

Recent developments in the adalimumab biosimilar market are driving increased competition and access, with improvements in the quality of biosimilars and cost reduction. This will lead to better treatment options, higher market access, and benefits for both patients and health systems.

Strategic Growth Opportunities for Adalimumab Biosimilar Market

All strategic growth opportunities in different applications are key segments of the adalimumab biosimilar market. A growing market is one where stakeholders realize significant opportunities for growth by responding to market demand and taking advantage of emerging trends. Key applications offer pronounced potential for growth and innovation.

• Market Expansion: Emerging Markets: Developing markets, especially in Asia and Latin America, will provide significant growth prospects for adalimumab biosimilars. This can be enabled by increasing demand for more affordable biologics within these regions. Other strategies include forming local partnerships for manufacturing and adopting pricing models designed to improve market access and meet regional healthcare needs.
• Development of New Biosimilar Products: There are further opportunities in the development of new adalimumab biosimilars with enhanced formulations or delivery methodologies. Product innovation may include extended-release formulations, combination therapies, or other forms that better meet patient needs. Investment in R&D for new biosimilar products can capture additional market share and drive further growth.
• Strategic Partnerships and Collaborations: Strategic partnerships between biosimilar manufacturers, healthcare providers, and payers can strengthen the market position of adalimumab biosimilars. Collaboration agreements may take various forms, such as joint ventures, co-marketing agreements, and distribution partnerships. Such alliances can offer access to markets, increase product visibility, and smoothen the adoption curve for biosimilars.
• Integration into Health Systems: Formulary inclusion and guidelines that integrate biosimilars into established health systems will continue to drive adoption. It is also essential to engage with healthcare authorities to ensure that biosimilars are included in treatment protocols and reimbursement schedules. This integration will contribute to broader use and cost savings in healthcare systems.
• Patient Education: Investments in patient education and awareness programs present a growth opportunity. Educating patients about the benefits and safety of biosimilars can overcome resistance and improve acceptance. Effective communication strategies and educational campaigns will boost patient confidence and facilitate a smooth transition to biosimilars.

Strategic growth opportunities in the adalimumab biosimilar market include expanding into emerging markets, leveraging cost advantages, and forming strategic partnerships. These opportunities will drive market expansion, enhance patient access, and foster innovation in biosimilar development.

Adalimumab Biosimilar Market Driver and Challenges

The market dynamics of adalimumab biosimilars are influenced by technological, economic, and regulatory factors that contribute to market growth and present considerable challenges. Stakeholders will need to be aware of these drivers and challenges to cope effectively with the dynamically changing landscape. All these factors-technological advancements, economic pressures, and regulatory changes-together shape the market dynamics, affecting everything from development and approval to market adoption and competition.

The factors responsible for driving the adalimumab biosimilar market include:

• Patent Expiration of Humira: The expiry of Humira's patent in 2023 is considered a leading driver for the biosimilar market. It paved the way for many biosimilars to enter the market, creating a competitive environment that drives prices down and expands access to biologic treatments. A patent cliff stimulates investment in the development of biosimilars and broadens treatment options for patients.
• Cost-Effectiveness: The key driver for the adoption of biosimilars is that they offer a less expensive alternative to originator biologic therapies. Healthcare systems and payers are increasingly focused on reducing drug costs, and biosimilars provide significant savings compared with branded biologics. This cost advantage encourages wide adoption and integration into treatment regimens.
• Regulatory Support: The FDA, along with other agencies like the EMA, has established regulatory frameworks that enable the approval and market entry of adalimumab biosimilars. Simplified approval processes, such as less elaborate clinical trials and more transparent guidelines, reduce obstacles to entry and accelerate their availability in the market.
• Increased Patient Demand: Growing patient demand for affordable, effective treatments is driving the adoption of biosimilars. As awareness of biosimilars rises, patients are increasingly seeking cost-saving treatments. This trend represents the general push toward more patient-centric and cost-efficient healthcare solutions.
• Pressure from the Healthcare System: There is mounting pressure on healthcare systems worldwide with respect to drug costs and access to treatments. Biosimilars provide a solution by offering similar therapeutic benefits at a lower cost. The economic burden on health budgets turns into a driver for the introduction of biosimilars, which help achieve cost savings while maintaining standards of treatment.

Challenges in the adalimumab biosimilar market include:

• Regulatory Hurdles: Despite supportive frameworks, the approval processes for biosimilars may remain cumbersome and divergent across regions. Navigating various regulatory requirements and demonstrating equivalence to the originator biologic requires substantial investment in clinical trials and documentation. These regulatory barriers could delay market entry and increase development costs.
• Market Acceptance: Sluggish market acceptance is a challenge, with concerns about the efficacy and safety of biosimilars compared to their originator biologic counterparts. Due to unfamiliarity or perceived risks, physicians and patients may resist switching, which will impact the rate of adoption. These obstacles can be overcome with robust evidence and effective educational initiatives.
• Disputes over Intellectual Property: Intellectual property issues, including patent disputes and litigations, are significant challenges faced by biosimilar developers. Legal battles over exclusivity and patent rights can delay market entry and increase costs. These disputes must be negotiated cautiously with the right legal approach, as they can affect competitive dynamics in the market.

The drivers in the adalimumab biosimilar market include patent expiration, cost-effectiveness, regulatory support, patient demand, and pressures from the healthcare system. On the other hand, challenges such as regulatory hurdles, market acceptance, and intellectual property disputes must be addressed. Together, these drivers and challenges influence market dynamics, affecting the rate of adoption, competition, and overall market growth. Capitalizing on these drivers will be key to overcoming the challenges.

List of Adalimumab Biosimilar Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies adalimumab biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adalimumab biosimilar companies profiled in this report include-

• Alfred E. Tiefenbacher
• Amgen
• Boehringer Ingelheim
• Glenmark
• Zydus
• Torrent Pharmaceuticals
• Reliance Life Sciences

Adalimumab Biosimilar by Segment

The study includes a forecast for the global adalimumab biosimilar market by product, end use, and region.

Adalimumab Biosimilar Market by Product [Analysis by Value from 2019 to 2031]:

• Exemptia
• Adalirel
• Cipleumab
• Others

Adalimumab Biosimilar Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals Pharmacies
• Retail Pharmacies
• Others

Adalimumab Biosimilar Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Adalimumab Biosimilar Market

In the wake of growing competition, changes in regulation, and evolving market dynamics, new and significant developments have been witnessed in the Adalimumab biosimilar market. With the expiration of patents for the original adalimumab, commonly referred to as Humira, biosimilars are being introduced as more affordable options. As a result, this has affected pricing, market access, and treatment options across diverse regions. Market dynamics in each country have influenced the adoption and growth of these biosimilars, which are driven by the regulatory environment, healthcare infrastructure, and economic considerations.

• United States: With the expiration of Humira's patent in 2023, the adalimumab biosimilar market saw rapid growth in the U.S. Other biosimilars, such as Amgen's Amesite and AbbVie's Hulin, have entered the market with competitive pricing. Favorable FDA approvals, along with growing healthcare cost containment pressures, have underpinned the increased adoption of these biosimilars. They continue to gain significant market share, though payer and provider education remain challenges.
• China: The biosimilar market is growing in China, as the NMPA fast-tracks approvals for Adalimumab biosimilars. Companies like Innocents Biologics and Coheres Biosciences are making significant inroads into the country. Recent price negotiations and government initiatives to provide more affordable drugs to the population have contributed to this growth. However, broader market penetration remains restricted due to a lack of physician awareness and disparities in healthcare infrastructure across geographical regions.
• Germany: With its strong healthcare infrastructure and favorable regulatory environment, Germany has become one of the largest adopters of adalimumab biosimilars in Europe. Recent developments include the increasing market share of biosimilars, such as BLAZIC, in the treatment of inflammatory diseases. The promotion of cost-effectiveness-achieved through competitive pricing-within the German healthcare system is driving the rising demand for biosimilars.
• India: The biosimilar market is developing in India, with growing interest from both domestic and international firms. Companies like Cadila Healthcare and Biocon have launched Adalimumab biosimilars for indications that leverage the large patient pool and expand healthcare infrastructure. Recent government policies have made healthcare more affordable, with price cuts increasing access to the market. However, stronger regulatory challenges and variability in quality standards continue to constrain the market.
• Japan: Entries from companies such as Pfizer and Samsung Biologics are increasing the Japanese market for Adalimumab biosimilars. In response, the PMDA (Pharmaceuticals and Medical Devices Agency) has simplified the approval process, facilitating the adoption of biosimilars. However, the high standards for clinical data and resistance from some physicians have slowed growth. The Japanese market is showing consistent, if not stellar, growth in biosimilars, supported by cost pressures and healthcare reforms.

Features of the Global Adalimumab Biosimilar Market

Market Size Estimates: Adalimumab biosimilar market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Adalimumab biosimilar market size by product, end use, and region in terms of value ($B).

Regional Analysis: Adalimumab biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, end uses, and regions for the adalimumab biosimilar market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adalimumab biosimilar market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the adalimumab biosimilar market by product (exemptia, adalirel, cipleumab, and others), end use (hospitals pharmacies, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Adalimumab Biosimilar Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Adalimumab Biosimilar Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Adalimumab Biosimilar Market by Product
  • 3.3.1: Exemptia
  • 3.3.2: Adalirel
  • 3.3.3: Cipleumab
  • 3.3.4: Others
• 3.4: Global Adalimumab Biosimilar Market by End Use
  • 3.4.1: Hospitals Pharmacies
  • 3.4.2: Retail Pharmacies
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Adalimumab Biosimilar Market by Region
• 4.2: North American Adalimumab Biosimilar Market
  • 4.2.1: North American Market by Product: Exemptia, Adalirel, Cipleumab, and Others
  • 4.2.2: North American Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
• 4.3: European Adalimumab Biosimilar Market
  • 4.3.1: European Market by Product: Exemptia, Adalirel, Cipleumab, and Others
  • 4.3.2: European Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
• 4.4: APAC Adalimumab Biosimilar Market
  • 4.4.1: APAC Market by Product: Exemptia, Adalirel, Cipleumab, and Others
  • 4.4.2: APAC Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
• 4.5: ROW Adalimumab Biosimilar Market
  • 4.5.1: ROW Market by Product: Exemptia, Adalirel, Cipleumab, and Others
  • 4.5.2: ROW Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Adalimumab Biosimilar Market by Product
  • 6.1.2: Growth Opportunities for the Global Adalimumab Biosimilar Market by End Use
  • 6.1.3: Growth Opportunities for the Global Adalimumab Biosimilar Market by Region
• 6.2: Emerging Trends in the Global Adalimumab Biosimilar Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Adalimumab Biosimilar Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Adalimumab Biosimilar Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Alfred E. Tiefenbacher
• 7.2: Amgen
• 7.3: Boehringer Ingelheim
• 7.4: Glenmark
• 7.5: Zydus
• 7.6: Torrent Pharmaceuticals
• 7.7: Reliance Life Sciences